Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FENC 
Fennec Pharmaceuticals Inc (FENC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: FENC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14
1 Year Target Price $14
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 21.5% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 241.90M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 5 | Beta 0.58 | 52 Weeks Range 3.96 - 9.42 | Updated Date 09/16/2025 |
52 Weeks Range 3.96 - 9.42 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.15% | Operating Margin (TTM) -28.31% |
Management Effectiveness
Return on Assets (TTM) -11.19% | Return on Equity (TTM) -1005.59% |
Valuation
Trailing PE - | Forward PE 15.41 | Enterprise Value 257729820 | Price to Sales(TTM) 7.26 |
Enterprise Value 257729820 | Price to Sales(TTM) 7.26 | ||
Enterprise Value to Revenue 7.74 | Enterprise Value to EBITDA 20.27 | Shares Outstanding 27831700 | Shares Floating 14528146 |
Shares Outstanding 27831700 | Shares Floating 14528146 | ||
Percent Insiders 16.25 | Percent Institutions 57.88 |
Upturn AI SWOT
Fennec Pharmaceuticals Inc
Company Overview
History and Background
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focusing on developing therapies for pediatric oncology. Founded to address unmet needs in cancer treatment, the company's primary focus has been on minimizing chemotherapy-induced toxicities in children.
Core Business Areas
- Pharmaceutical Development: Focuses on researching, developing, and commercializing pharmaceutical products. Currently developing PEDMARKu00ae (sodium thiosulfate) to reduce ototoxicity induced by cisplatin chemotherapy.
- Commercialization: Involves the marketing and distribution of approved pharmaceutical products. Preparing for the commercial launch of PEDMARKu00ae.
Leadership and Structure
Rostislav Raykov, CEO; Robert Andrade, CFO. The company operates with a functional organizational structure, focusing on clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- PEDMARKu00ae (sodium thiosulfate): PEDMARKu00ae is indicated to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients 1 month to <18 years of age with localized, non-metastatic solid tumors. Although approved, it is a fairly new drug and revenue estimates are starting at around $20M per year. The competitors are any other drugs that would achieve the same result of preventing hearing loss from Cisplatin chemotherapy. No other drug is currently FDA approved with this indication.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The pediatric oncology segment has a significant unmet need for therapies that reduce treatment-related toxicities.
Positioning
Fennec is positioned as a specialty pharmaceutical company focused on addressing critical unmet needs in pediatric oncology, particularly the reduction of chemotherapy-induced toxicities. Their competitive advantage lies in the FDA approval of PEDMARKu00ae, a unique therapy for preventing cisplatin-induced ototoxicity. They are now a commercial entity, with that risk now added.
Total Addressable Market (TAM)
The TAM for preventing cisplatin-induced ototoxicity in pediatric cancer patients is estimated to be in the range of $200 million annually in the US alone. Fennec, with PEDMARKu00ae, is positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- FDA-approved product (PEDMARKu00ae)
- First and only approved treatment for cisplatin-induced ototoxicity
- Strong intellectual property protection
- Experienced management team
Weaknesses
- Solely dependent on a single product
- Commercial execution risk
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on third-party manufacturers
Opportunities
- Expansion into other geographic markets
- Potential for label expansion to other patient populations
- Partnerships with larger pharmaceutical companies
- Development of additional therapies for pediatric oncology
Threats
- Competition from alternative therapies or preventative measures
- Regulatory challenges
- Reimbursement pressures from payers
- Adverse events associated with PEDMARKu00ae
Competitors and Market Share
Key Competitors
- There are no directly competitive drugs with the same indication as PEDMARKu00ae. Instead consider generic Sodium Thiosulfate
- (TEVA)
- (MYL)
- (PFE)
Competitive Landscape
Fennec has a monopoly until a similar drug gets approved.
Growth Trajectory and Initiatives
Historical Growth: Limited historical revenue growth due to pre-commercialization stage.
Future Projections: Analyst estimates project significant revenue growth in the coming years driven by PEDMARKu00ae sales. Profitability is expected to improve as sales volume increases.
Recent Initiatives: Focus on commercial launch of PEDMARKu00ae, building a sales and marketing team, and securing reimbursement agreements.
Summary
Fennec Pharmaceuticals is a high-risk, high-reward investment. PEDMARKu00ae's FDA approval presents a significant opportunity, but successful commercialization is crucial. The company's financial health depends on generating sufficient revenue and managing expenses. Investors should monitor sales performance, reimbursement coverage, and competitive developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fennec Pharmaceuticals Inc. SEC filings
- Analyst reports
- Company presentations
- FDA website
- Company website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimations are approximations based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fennec Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 2001-06-05 | CEO & Director Mr. Jeffrey S. Hackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://fennecpharma.com |
Full time employees 32 | Website https://fennecpharma.com | ||
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.